INTRODUCTION: Leber hereditary optic neuropathy (LHON) is the most commonly diagnosed mitochondrial disorder, resulting in colour vision abnormalities and rapid but painless deterioration of central vision. While numerous studies have assessed the impact of LHON on the quality of life (QoL) of LHON patients, the financial impact of the disease remains unexplored. This study attempts to calculate both the direct non-medical costs and the indirect costs associated with productivity losses experienced by people with LHON and their unpaid caregivers in Slovenia, in addition to assessing their QoL. Due to the rarity of the disease, the study involved a small sample size, which is important to note for interpreting the results. METHODS: The analysis was conducted on nine adult participants diagnosed with LHON, representing one-third of the total number of known Slovenian patients with this condition. To thoroughly assess the economic and social impact of LHON, tailored questionnaires were designed to collect information on demographics, socioeconomic status, LHON severity, and associated non-medical and indirect costs. RESULTS: The mean age of the study participants was 48.8 years (SD 13.3; n = 9). The annual productivity loss attributable to LHON, taking both absenteeism and relative presenteeism into account, was calculated to be EUR 11,608 per person affected. The mean VFQ-25 score, a measure of vision-related quality of life, for adult LHON patients was 30.4 (SD 12.9). CONCLUSION: The findings highlight the significant economic and social burden of LHON on patients and their families. Ensuring prompt, accurate diagnosis, access to treatment, financial support, and psychological counselling and services are critical to helping individuals cope with and mitigate the profound challenges of vision loss and living with LHON.

CEEOR s r o Prague Czechia

Department of Biomedical Technology Faculty of Biomedical Engineering Czech Technical University Prague Kladno Czechia

Department of Pharmacy and Social Pharmacy University of Veterinary Medicine and Pharmacy Košice Košice Slovakia

Department of Public Economics Faculty of Economics and Administration Masaryk University Brno Brno Czechia

Eye Hospital University Medical Centre Ljubljana Ljubljana Slovenia

See more in PubMed

Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF. Inherited mitochondrial optic neuropathies. J Med Genet. 2008;46:145–58. 10.1136/jmg.2007.054270. 10.1136/jmg.2007.054270 PubMed DOI PMC

Man PYW. Leber hereditary optic neuropathy. J Med Genet. 2002;39:162–9. 10.1136/jmg.39.3.162. 10.1136/jmg.39.3.162 PubMed DOI PMC

Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AMS, Elsas LJ, Nikoskelainen EK. Mitochondrial DNA mutation Associated with Lebers Hereditary Optic Neuropathy. Science. 1979;242(1988):1427–30. 10.1126/science.3201231.10.1126/science.3201231 PubMed DOI

Oostra RJ, Bolhuis PA, Wijburg FA, Zorn-Ende G, Bleeker-Wagemakers EM. Lebers hereditary optic neuropathy: correlations between mitochondrial genotype and visual outcome. J Med Genet. 1994;31:280–6. 10.1136/jmg.31.4.280. 10.1136/jmg.31.4.280 PubMed DOI PMC

Hage R, Vignal-Clermont C. Leber Hereditary Optic Neuropathy: review of treatment and management. Front Neurol. 2021;12. 10.3389/fneur.2021.651639. PubMed PMC

Petrovic Pajic S, Jarc-Vidmar M, Fakin A, Sustar Habjan M, Brecelj J, Volk M, Maver A, Peterlin B, Hawlina M. Case report: long-term follow-up of two patients with LHON caused by DNAJC30:c.152G > A pathogenic variant-case series. Front Neurol. 2022;13. 10.3389/fneur.2022.1003046. PubMed PMC

Stenton SL, Sheremet NL, Catarino CB, Andreeva NA, Assouline Z, Barboni P, Barel O, Berutti R, Bychkov I, Caporali L, Capristo M, Carbonelli M, Cascavilla ML, Charbel Issa P, Freisinger P, Gerber S, Ghezzi D, Graf E, Heidler J, Hempel M, Heon E, Itkis YS, Javasky E, Kaplan J, Kopajtich R, Kornblum C, Kovacs-Nagy R, Krylova TD, Kunz WS, La Morgia C, Lamperti C, Ludwig C, Malacarne PF, Maresca A, Mayr JA, Meisterknecht J, Nevinitsyna TA, Palombo F, Pode-Shakked B, Shmelkova MS, Strom TM, Tagliavini F, Tzadok M, Van der Ven AT, Vignal-Clermont C, Wagner M, Zakharova EY, Zhorzholadze NV, Rozet JM, Carelli V, Tsygankova PG, Klopstock T, Wittig I, Prokisch H. Impaired complex I repair causes recessive Leber’s hereditary optic neuropathy. J Clin Invest. 2021;131. 10.1172/JCI138267. PubMed PMC

Puomila A, Hämäläinen P, Kivioja S, Savontaus M-L, Koivumäki S, Huoponen K, Nikoskelainen E. Epidemiology and penetrance of Leber hereditary optic neuropathy in Finland. Eur J Hum Genet. 2007;15:1079–89. 10.1038/sj.ejhg.5201828. 10.1038/sj.ejhg.5201828 PubMed DOI

Mascialino B, Leinonen M, Meier T. Meta-analysis of the prevalence of Leber hereditary optic neuropathy mtDNA mutations in Europe. Eur J Ophthalmol. 2011;22:461–5. 10.5301/ejo.5000055.10.5301/ejo.5000055 PubMed DOI

Man PYW, Griffiths PG, Brown DT, Howell N, Turnbull DM, Chinnery PF. The epidemiology of Leber Hereditary Optic Neuropathy in the North East of England. Am J Hum Genet. 2003;72:333–9. 10.1086/346066. 10.1086/346066 PubMed DOI PMC

Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, Feeney C, Horvath R, Yu-Wai‐Man P, Chinnery PF, Taylor RW, Turnbull DM, McFarland R. Prevalence of nuclear and mitochondrial < scp > DNA mutations related to adult mitochondrial disease. Ann Neurol. 2015;77:753–9. 10.1002/ana.24362. 10.1002/ana.24362 PubMed DOI PMC

Šega R, Burgar J, Fakin A, Petrović Pajić S, Volk M, Hawlina M, Glavač D. Jarc-Vidmar, Leberjeva hereditarna optična nevropatija – pregled bolezni z analizo prisotnosti v Sloveniji. Slovenian Med J. 2022;1–14. 10.6016/ZdravVestn.3234.

Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, Atawan A, Chattopadhyay S, Schubert M, Garip A, Kernt M, Petraki D, Rummey C, Leinonen M, Metz G, Griffiths PG, Meier T, Chinnery PF. A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain. 2011;134:2677–86. 10.1093/brain/awr170. 10.1093/brain/awr170 PubMed DOI PMC

Carelli V, Carbonelli M, De Coo IF, Kawasaki A, Klopstock T, Lagrèze WA, La Morgia C, Newman NJ, Orssaud C, Pott JWR, Sadun AA, Van Everdingen J, Vignal-Clermont C, Votruba M, Yu-Wai-Man P, Barboni P. International consensus statement on the clinical and therapeutic management of leber hereditary optic neuropathy. J Neuroophthalmol. 2017;37:371–81. 10.1097/WNO.0000000000000570. 10.1097/WNO.0000000000000570 PubMed DOI

Catarino CB, von Livonius B, Priglinger C, Banik R, Matloob S, Tamhankar MA, Castillo L, Friedburg C, Halfpenny CA, Lincoln JA, Traber GL, Acaroglu G, Black GCM, Doncel C, Fraser CL, Jakubaszko J, Landau K, Langenegger SJ, Muñoz-Negrete FJ, Newman NJ, Poulton J, Scoppettuolo E, Subramanian P, Toosy AT, Vidal M, Vincent AL, Votruba M, Zarowski M, Zermansky A, Lob F, Rudolph G, Mikazans O, Silva M, Llòria X, Metz G. Klopstock, Real-World Clinical Experience with Idebenone in the treatment of Leber Hereditary Optic Neuropathy. J Neuroophthalmol. 2020;40:558–65. 10.1097/WNO.0000000000001023. 10.1097/WNO.0000000000001023 PubMed DOI PMC

Pemp B, Kircher K, Reitner A. Visual function in chronic Leber’s hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset. Graefe’s Archive Clin Experimental Ophthalmol. 2019;257. 10.1007/s00417-019-04444-6. PubMed

Baltă G, Cristache G, Barac AD, Anton N, Barac IR. Leber’s Hereditary Optic Neuropathy (LHON): clinical experience and outcomes after long-term Idebenone Treatment. Life. 2023;13. 10.3390/life13102000. PubMed PMC

Ferguson J, de Abreu G. What is the lived experience for people with Leber Hereditary Optic Neuropathy? Br J Visual Impairment. 2016;34:109–20. 10.1177/0264619615616260.10.1177/0264619615616260 DOI

Kirkman MA, Korsten A, Leonhardt M, Dimitriadis K, de Coo IF, Klopstock T, Griffiths PG, Hudson G, Chinnery PF. Yu-Wai-Man, Quality of life in patients with leber hereditary optic neuropathy. Invest Ophthalmol Vis Sci. 2009;50:3112–5. 10.1167/iovs.08-3166. 10.1167/iovs.08-3166 PubMed DOI

Cui S, Jiang H, Peng J, Wang J, Zhang X. Evaluation of vision-related quality of life in Chinese patients with Leber Hereditary Optic Neuropathy and the G11778A mutation. J Neuroophthalmol. 2019;39:56–9. 10.1097/WNO.0000000000000644. 10.1097/WNO.0000000000000644 PubMed DOI

Kessler RC, Barber C, Beck A, Berglund P, Cleary PD, McKenas D, Pronk N, Simon G, Stang P, Ustun TB, Wang P. The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med. 2003;45:156–74. 10.1097/01.jom.0000052967.43131.51. 10.1097/01.jom.0000052967.43131.51 PubMed DOI

Mangione CM. Development of the 25-list-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050. 10.1001/archopht.119.7.1050. 10.1001/archopht.119.7.1050 PubMed DOI

Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, Kennedy A. The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. 2022;17:163. 10.1186/s13023-022-02299-5. 10.1186/s13023-022-02299-5 PubMed DOI PMC

Gong J, Cheung S, Fasso-Opie A, Galvin O, Moniz LS, Earle D, Durham T, Menzo J, Li N, Duffy S, Dolgin J, Shearman MS, Fiorani C, Banhazi J, Daly A. The impact of inherited retinal diseases in the United States of America (US) and Canada from a cost-of-illness perspective. Clin Ophthalmol. 2021;15:2855–66. 10.2147/OPTH.S313719. 10.2147/OPTH.S313719 PubMed DOI PMC

Galvin O, Chi G, Brady L, Hippert C, Rubido MDV, Daly A, Michaelides M. The impact of inherited retinal diseases in the Republic of Ireland (ROI) and the United Kingdom (UK) from a cost-of-illness perspective. Clin Ophthalmol Volume. 2020;14:707–19. 10.2147/opth.s241928.10.2147/opth.s241928 PubMed DOI PMC

Garcia GA, Khoshnevis M, Gale J, Frousiakis SE, Hwang TJ, Poincenot L, Karanjia R, Baron D, Sadun AA. Profound vision loss impairs psychological well-being in young and middle-aged individuals. Clin Ophthalmol. 2017;11. 10.2147/OPTH.S113414. PubMed PMC